

2024 WuXi AppTec Investor Day

Industry Trend

Edward Hu

Vice Chairman & Global Chief Investment Officer

Forward-Looking Statements

This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings or production capacity, our ability to reach the scale of our production capacity expansion plans, our ability to protect our clients’ intellectual property, competition, unforeseeable change of international policy, the impact of emergencies and other force majeure. Our forward-looking statements do not constitute any profit forecast by our management nor a undertaking by WuXi AppTec Co., Ltd. (“WuXi AppTec” or the “Company”) to our investors. **ACCORDINGLY, YOU ARE STRONGLY CAUTIONED THAT RELIANCE ON ANY FORWARD-LOOKING STATEMENTS INVOLVES KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES.** All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement or information in this presentation to reflect future events or circumstances, except as required under applicable law.

Non-IFRS Financial Measures

We provide non-IFRS gross profit and non-IFRS net profit attributable to the owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses and amortization of acquired intangible assets from merger and acquisition, non-financial assets impairment, etc. We also provide adjusted non-IFRS net profit attributable to the owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither of the above is required by, or presented in accordance with IFRS.

We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such non-IFRS financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

Intellectual Property

All intellectual property rights and other rights pertaining to the information and materials presented in the presentation are owned by WuXi AppTec. Audio recording, video recording or disclosure of such materials by any means without the prior consent of WuXi AppTec is prohibited.

Disclaimer


This presentation is for information purposes only and does not constitute a recommendation regarding any securities of the Company. This presentation does not intend to provide a complete statement relating to the Company, its securities, or any relevant matters herein that a recipient may need in order to evaluate the Company. For relevant information, please refer to the Company’s disclosure documents and information on the Shanghai Stock Exchange, the Stock Exchange of Hong Kong Limited and the Company’s website.

Innovations Continue to Drive Approvals of New Drugs for Patients in Need

FDA Approved 51 Drugs per Year on Average since 2015. Expecting Another ~50 Approvals in 2024 after the Record Year of 2023

FDA New Drug Approvals by Modality, 2015 - H1 2024

of drugs




3 Source: FDA (CDER & CBER); internal analysis.
This analysis includes novel approvals and therapeutics only.

Global R&D Pipelines Keep Growing Steadily over Past Years

Small Molecule Remains the Dominant Modality, while New Modalities Increase Rapidly

Global R&D Pipeline by Modality, 2015-2023




Steady Growth of Global R&D Expenses across the Pharmaceutical Industry

Global R&D Spending Continue to Grow at 6.6% CAGR 2023-2028E, ~80% Share Contributed by Large and Mid-size Pharmas Today; Small Biopharmas Expect to Increase Share from ~20% Today to ~30% by 2033E with ~10% CAGR

Global R&D Expenses by Pharma Size, 2015-2033E


Period	Large Pharmas	Mid-size Pharmas	Small Pharmas/ Biotechs/Virtual Pharmas	Total
2015-2023	6.2%	6.4%	8.8%	6.7%
2023-2028E	4.8%	6.7%	10.8%	6.6%
2028E-2033E	3.2%	4.3%	9.7%	5.2%



Scientific Innovations Continue to Generate ~1,000 New Companies Each Year

Large and Mid-size Pharmas Account for ~20%, while Small Biopharmas Expands to ~80% in 2024

Number of Global Pharmaceutical Companies, 2015-2033E




Innovators Across Regions Ensure the Continuous Emergence of Innovation

In Addition to US, Both Europe & China are Important Innovation Hubs with ~50% as Many Companies as US

Number of Pharmaceutical Companies by Development Phase

of companies




7 Source: Cortellis, July 31 2024; internal analysis.

This analysis includes companies with drug(s) from discovery to launched phase, and development phase is based on the highest R&D stage among all pipelines within the company.


Despite Funding Challenges in Recent Years, the Rising Upfront Payments from Deals Provide Another Key Alternative for Innovators to Source Capital

Deal Upfront Payments Provided Biopharmas with Twice as Much Capital as VC Funding in 2023

VC Financing vs Deal Upfront Payments, 2019 - 2023



Global Biopharma Deals by Total Value & Volume, 2019 - 2023



Licensing and M&A Remain Key Strategies for Biopharmas to Accelerate Pipeline Replenishment and Mitigate Potential Impacts from IRA and Patent Expiration

Top 10 Licensing Deals by Upfront Value, H1 2024

Date	Licensee	Licensor	Upfront (\$Bn)	Total (\$Bn)
2024/02	Sanofi	Novavax	0.5	1.2
2024/05	Viartis	Idorsia	0.4	/
2024/01	Novartis	Argo	0.2	4.2
2024/04	Novartis	PeptiDream	0.2	2.9
2024/04	Sandoz	Coherus	0.2	/
2024/04	Novartis	Arvinas	0.2	1.2
2024/04	Shionogi	Maze	0.2	/
2024/05	AbbVie	FutureGen	0.2	1.7
2024/01	Novartis	Voyager	0.1	1.3
2024/01	Kyowa Kirin	Bridgebio	0.1	/


Top 10 M&A Deals by Total Value, H1 2024

Date	Acquirer	Target	Upfront (\$Bn)	Value (\$Bn)
2024/04	Vertex	Alpine Immune	/	4.9
2024/02	Gilead	CymaBay	/	4.3
2024/05	Merck & Co.	EyeBiotech	1.3	3.0
2024/02	Novartis	MorphoSys	/	2.9
2024/04	Ono	Deciphera	2.0	2.4
2024/03	AstraZeneca	Fusion	/	2.4
2024/01	J&J	Ambrx Biopharma	/	2.0
2024/04	Genmab	ProfoundBio	/	1.8
2024/05	Biogen	HI-Bio	1.2	1.8
2024/05	Norvatis	Mariana Oncology	1.0	1.8


Global Biotech Funding Also Sees Strong Rebound in H1 2024

2023 Funding Back to Pre-pandemic Level. H1 2024 Up 63% YoY, Mostly Driven by FO & PIPE (Up 80% YoY / 75% Value Contribution); VC Also Up 45% YoY, with Fewer But Higher-Value Deals

Global Biotech Funding by Quarter (IPO + FO + PIPE + VC), Q1 2015 - Q2 2024




VC Funding by Modality, H1 2024



China Biotech Industry Experienced Rapid Growth over the Past Few Years

Despite Current Funding Challenges, China Biotechs are Gaining Enhanced Recognition in Global Markets

China Biotech's Out-licensing to Global Companies, 2019 - H1 2024



Top 10 China Biotech's Out-licensing Deals to Global Companies since 2020

Date	Licensee	Licensor	Upfront (\$Bn)	Total (\$Bn)
2024/01	Novartis	Argo	0.2	4.2
2023/12	BMS	Systimmune	0.8	8.4
2023/11	AstraZeneca	Chengyi Biological Technology	0.2	2.0
2023/05	Janssen	Cellular Biomedicine	0.2	/
2023/01	Takeda	Hutchmed	0.4	1.1
2022/12	Summit	Akeso	0.5	5.0
2021/12	Novartis	BeiGene	0.3	2.9
2021/08	Seagen	RemeGen	0.2	2.6
2021/01	Novartis	BeiGene	0.7	2.2
2020/08	Lilly	Innovent Biologics	0.2	1.0

China Biotech Acquired by Global Companies since 2018

Date	Acquirer	Target	Upfront (\$Bn)	Value (\$Bn)
2024/08	MSD	Curon Biopharma (asset) ¹	0.7	1.3
2024/04	Genmab	ProfoundBio	/	1.8
2024/03	Nuvation Bio	AnHeart Therapeutics	/	0.3
2024/01	Novartis	SanReno	/	3.5
2023/12	AstraZeneca	Gracell Biotechnologies	1.0	1.2
2023/10	Gyre Therapeutics	Continent Pharma	N/A (Merger)	
2023/02	Kinnate Biopharma	Kinnjiu Biopharma	/	0.02

11 Source: Frost & Sullivan, July 2024; internal analysis.
Note: 1. Curon Biopharma (CN201).

FDA & EMA Approved Increasing Number of Innovative New Drugs Originated from China Biotechs in Recent Years

Drugs Originated from China Biotech Approved by FDA, 2019-2024¹

Approval Date	Originator	Drug Name
2024/03	BeiGene	Tislelizumab
2023/11	Yifan Pharmaceutical	Efbemalenograstim alfa
2023/11	Hutchmed Limited	Fruquintinib
2023/10	Junshi Biosciences	Toripalimab
2022/02	Legend Biotech	Ciltacabtagene autoleucel (Carvykti)
2019/11	BeiGene	Zanubrutinib (Brukinsa)


Drugs Originated from China Biotech Approved by EMA, 2019-2024¹

Approval Date	Originator	Drug Name
2024/07	Cstone Pharmaceuticals	Sugemalimab
2024/06	Hutchmed Limited	Fruquintinib
2024/03	Yifan Pharmaceutical	Efgbemalenograstim alfa
2023/09	BeiGene	Tislelizumab
2022/05	Legend Biotech	Ciltacabtagene autoleucel
2021/11	BeiGene	Zanubrutinib
2021/09	Junshi Biosciences	Etesevimab

China Biotechs can Bring Great Reward to Global Partners and Investors

With Today's Better Developed Ecosystem, China Biotech Industry is Entering the Global Stage for the Next 10 Years to Come


Share Price Trend of Akeso Bio and Summit



Global Outsourcing Market Continues to Expand

Outsourcing Penetration Gradually Elevates to >50% in 2024 and Expect to Reach ~65% in 2033E, as the Pharmaceutical Industry Continues to Accelerate Pipeline Progress and Improve Efficiency, Create Value to Shareholders and for Patients

Global CRO Outsourcing Rate, 2015-2033E




Global Outsourcing Market Grows Faster than Overall R&D Spending

Global Outsourcing Market Growing at 12.0% CAGR 2023-2028E, and Momentum Expected to Continue for Many Years to Come

Global Pharmaceutical R&D Outsourcing Market, 2015-2033E

Period	Discovery	Preclinical	Clinical	Small molecule CDMO	Including: Peptide CDMO	Including: Oligo CDMO	CGT CDMO	Total
2015-2023	10.2%	7.8%	9.0%	10.4%	14.3%	75.9%	18.9%	9.7%
2023-2028E	9.4%	8.9%	8.1%	15.5%	23.7%	26.3%	23.9%	11.8%
2028E-2033E	9.2%	8.9%	7.7%	16.1%	18.9%	24.5%	27.7%	12.9%

USD billion



With Customers as our Top Priority, Demand for Our Integrated CRDMO Services will Continue to Grow Despite External Challenges

Biotech Companies

- Advance new drug pipeline ahead of competition
- Improve cost efficiency
- Extend cash runway
- Achieve the next value creation milestones
- Create equity value for shareholders

Large Pharmas

- In constant need to replenish pipeline via:
 - More efficient drug development through outsourcing
 - External M&A or licensing
- Trusted partnership with proven track record



Our Unique CRDMO Business Model Positions the Company to Continue Growth in Both Good and Challenging Times

With emerging scientific innovations, global pharmaceutical companies constantly seek to bring **new and groundbreaking therapies** to patients in need, and create value to shareholders

01

02

Quality, speed and cost efficiency matter, as global pharmaceutical companies devote their efforts to accelerate pipeline and improve efficiency, and thus the **need for our services**

03

As a highly efficient enabler to the industry, our **unique integrated CRDMO business model** can effectively meet the growing demand of customers worldwide, and **continue to drive solid business growth**

04

CRDMO business model enables the Company to closely **follow scientific innovations, develop distinct industry insights**, and instantly **seize opportunities in new molecules** as they rise

05

Despite external challenges, our strong management team has the experience and capability to address difficulties, and consistently deliver for our **partners** and **shareholders**